efanesoctocog alfa

Efanesoctocog alfa is a recombinant DNA-derived Factor VIII (FVIII) concentrate designed for the treatment of hemophilia A, a congenital FVIII deficiency. It is a von Willebrand factor (VWF)-independent, extended half-life FVIII replacement therapy that temporarily replaces missing coagulation FVIII, thereby restoring the clotting cascade and enabling effective blood clot formation. The drug consists of an engineered fusion protein containing B-domain deleted human FVIII fused to XTEN polypeptides and Fc domains, as well as VWF D’D3 domains to enhance pharmacokinetics and stability. Efanesoctocog alfa is administered intravenously once weekly and provides normal to near-normal FVIII activity levels for most of the week. It was developed by Bioverativ Therapeutics (a Sanofi company) in collaboration with Swedish Orphan Biovitrum AB (Sobi). Its primary indication is for routine prophylaxis, on-demand treatment, control of bleeding episodes, and perioperative management in adults and children with hemophilia A[2][3][4][5][6][7].

Brand names

Altuviiio

Other names

antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl